Brent M Egan

List of Publications by Year
in descending order

111 papers	8,008 citations	117453 34 h-index	48187 88 g-index
115 all docs	115 docs citations	115 times ranked	9064 citing authors

#	Article	IF	Citations
1	US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008. JAMA - Journal of the American Medical Association, 2010, 303, 2043.	3.8	1,689
2	Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. New England Journal of Medicine, 2006, 354, 1685-1697.	13.9	854
3	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension, 2018, 72, e53-e90.	1.3	629
4	Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008. Circulation, 2011, 124, 1046-1058.	1.6	519
5	Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control Goals. Hypertension, 2006, 47, 345-351.	1.3	445
6	Adherence in Hypertension. Circulation Research, 2019, 124, 1124-1140.	2.0	401
7	The CardioMetabolic Health Alliance. Journal of the American College of Cardiology, 2015, 66, 1050-1067.	1.2	211
8	Initial Monotherapy and Combination Therapy and Hypertension Control the First Year. Hypertension, 2012, 59, 1124-1131.	1.3	183
9	Hypertension in the United States, 1999 to 2012. Circulation, 2014, 130, 1692-1699.	1.6	176
10	Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network. Hypertension, 2013, 62, 691-697.	1.3	137
11	Aldosterone in obesity. Endocrine Research, 1998, 24, 789-796.	0.6	135
12	Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients. Circulation, 2013, 128, 29-41.	1.6	123
13	Plasma Renin Test-Guided Drug Treatment Algorithm for Correcting Patients With Treated but Uncontrolled Hypertension: A Randomized Controlled Trial. American Journal of Hypertension, 2009, 22, 792-801.	1.0	119
14	Awareness, Knowledge, and Attitudes of Older Americans About High Blood Pressure. Archives of Internal Medicine, 2003, 163, 681.	4.3	117
15	The global burden of hypertension exceeds 1.4 billion people. Journal of Hypertension, 2019, 37, 1148-1153.	0.3	116
16	Insulin resistance and the sympathetic nervous system. Current Hypertension Reports, 2003, 5, 247-254.	1.5	112
17	Fatty Acids Enhance Vascular Î±-Adrenergic Sensitivity. Hypertension, 1995, 25, 774-778.	1.3	107
18	Progression Is Accelerated From Prehypertension to Hypertension in Blacks. Hypertension, 2011, 58, 579-587.	1.3	104

#	Article	IF	Citations
19	Trends in Prehypertension and Hypertension Risk Factors in US Adults. Hypertension, 2017, 70, 275-284.	1.3	101
20	Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension, 2022, 79, e1-e14.	1.3	97
21	Visceral adiposity syndrome. Diabetology and Metabolic Syndrome, 2016, 8, 40.	1.2	85
22	Insulin resistance and cardiovascular disease. American Journal of Hypertension, 2001, 14, S116-S125.	1.0	80
23	Reactive Oxygen Species Are Critical in the Oleic Acidâ€“Mediated Mitogenic Signaling Pathway in Vascular Smooth Muscle Cells. Hypertension, 1998, 32, 1003-1010.	1.3	74
24	Relationships Among Plasma Aldosterone, High-Density Lipoprotein Cholesterol, and Insulin in Humans. Hypertension, 1995, 25, 30-36.	1.3	73
25	Oleic Acidâ€“Induced Mitogenic Signaling in Vascular Smooth Muscle Cells. Circulation Research, 1996, 79, 611-619.	2.0	65
26	Signaling Events Mediating the Additive Effects of Oleic Acid and Angiotensin II on Vascular Smooth Muscle Cell Migration. Hypertension, 2001, 37, 308-312.	1.3	62
27	Obesity Hypertension Is Related More to Insulinâ€™s Fatty Acid Than Glucose Action. Hypertension, 1996, 27, 723-728.	1.3	57
28	The Growing Gap in Hypertension Control Between Insured and Uninsured Adults. Hypertension, 2014, 64, 997-1004.	1.3	55
29	Social and Medical Determinants of Cardiometabolic Health: The Big Picture. Ethnicity and Disease, 2015, 25, 521.	1.0	55
30	Improving Hypertension Control in Primary Care With the Measure Accurately, Act Rapidly, and Partner With Patients Protocol. Hypertension, 2018, 72, 1320-1327.	1.3	50
31	Hypertension Control in the United States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age- and Race-Ethnicity Groups. Hypertension, 2021, 78, 578-587.	1.3	49
32	Metabolic syndrome and insulin resistance in the TROPHY sub-study: Contrasting views in patients with high-normal blood pressure. American Journal of Hypertension, 2005, 18, 3-12.	1.0	45
33	Nonesterified fatty acids in blood pressure control and cardiovascular complications. Current Hypertension Reports, 2001, 3, 107-116.	1.5	44
34	Does Dark Chocolate Have a Role in the Prevention and Management of Hypertension?. Hypertension, 2010, 55, 1289-1295.	1.3	39
35	Cardioprotection: The Role of Î²â€Blocker Therapy. Journal of Clinical Hypertension, 2005, 7, 409-416.	1.0	34
36	Closing the Gap in Hypertension Control Between Younger and Older Adults. Circulation, 2014, 129, 2052-2061.	1.6	34

#	Article	IF	Citations
37	Blood Pressure and Metabolic Responses to Moderate Sodium Restriction in Isradipine-Treated Hypertensive Patients. American Journal of Hypertension, 1997, 10, 68-76.	1.0	33
38	Prehypertension: An Opportunity for a New Public Health Paradigm. Cardiology Clinics, 2010, 28, 561-569.	0.9	31
39	Measure Accurately, Act Rapidly, and Partner With Patients (<scp>MAP</scp>) improves hypertension control in medically underserved patients: Care Coordination Institute and American Medical Association Hypertension Control Project Pilot Study results. Journal of Clinical Hypertension, 2018, 20, 79-87.	1.0	31
40	Vascular Compression of the Rostral Ventrolateral Medulla in Sympathetic Mediated Essential Hypertension. Hypertension, 2000, 36, 78-82.	1.3	30
41	Different Definitions of Prevalent Hypertension Impact: The Clinical Epidemiology of Hypertension and Attainment of Healthy People Goals. Journal of Clinical Hypertension, 2013, 15, 154-161.	1.0	29
42	2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals. Journal of the American Heart Association, 2016, 5, .	1.6	29
43	Physical Activity and Hypertension. Hypertension, 2017, 69, 404-406.	1.3	29
44	Prehypertension: Risk stratification and management considerations. Current Hypertension Reports, 2008, 10, 359-366.	1.5	27
45	Role of Aldosterone Blockade in Resistant Hypertension. Seminars in Nephrology, 2014, 34, 273-284.	0.6	25
46	Sociodemographic Determinants of Lifeâ€™s Simple 7: Implications for Achieving Cardiovascular Health and Health Equity Goals. Ethnicity and Disease, 2020, 30, 637-650.	1.0	25
47	Controlling Blood Pressure in 50% of All Hypertensive Patients: An Achievable Goal in the Healthy People 2010 Report?. Journal of Investigative Medicine, 2003, 51, 373-385.	0.7	24
48	American Society of Hypertension regional chapters: leveraging the impact of the clinical hypertension specialist in the local community. American Journal of Hypertension, 2002, 15, 372-379.	1.0	23
49	Age and sex disparities in hypertension control: The multi-ethnic study of atherosclerosis (MESA). American Journal of Preventive Cardiology, 2021, 8, 100230.	1.3	22
50	Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines. Hypertension, 2016, 68, 318-323.	1.3	21
51	Impacting Population Cardiovascular Health Through a Communityâ€Based Practice Network: Update on an ASHâ€Supported Collaborative. Journal of Clinical Hypertension, 2011, 13, 543-550.	1.0	20
52	Blood Pressure, Heart Rate, and CNS Stimulant Medication Use in Children with and without ADHD: Analysis of NHANES Data. Frontiers in Pediatrics, 2014, 2, 100.	0.9	20
53	A cluster-based approach for integrating clinical management of Medicare beneficiaries with multiple chronic conditions. PLoS ONE, 2019, 14, e0217696.	1.1	17
54	Review: Prehypertension: should we be treating with pharmacologic therapy?. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 305-314.	1.0	16

#	Article	IF	Citations
55	Is blood pressure control to less than 140/less than 90 mmHg in 50% of all hypertensive patients as good as we can do in the USA: or is this as good as it gets?. Current Opinion in Cardiology, 2011, 26, 300-307.	0.8	16
56	Nicotine replacement therapy sampling via primary care: Methods from a pragmatic cluster randomized clinical trial. Contemporary Clinical Trials, 2018, 72, 1-7.	0.8	14
57	Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. Current Medical Research and Opinion, 2004, 20, 1909-1917.	0.9	13
58	Cardiovascular Risk Factor Control in Communities?Update From the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network. Journal of Clinical Hypertension, 2006, 8, 879-886.	1.0	13
59	Combination Therapy With an Angiotensinâ€Converting Enzyme Inhibitor and a Calcium Channel Blocker. Journal of Clinical Hypertension, 2007, 9, 783-789.	1.0	13
60	Prediction of incident hypertension. Health implications of data mining in the â€˜Big Dataâ€™ era. Journal of Hypertension, 2013, 31, 2123-2124.	0.3	13
61	Hypertension in African Americans Aged 60 to 79ÂYears: Statement From the International Society of Hypertension in Blacks. Journal of Clinical Hypertension, 2015, 17, 252-259.	1.0	12
62	The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents. American Journal of Hypertension, 2001, 14, 1032-1037.	1.0	11
63	Diabetes and age-related demographic differences in risk factor control. Journal of the American Society of Hypertension, 2014, 8, 394-404.	2.3	11
64	Cholesterol Control Among Uninsured Adults Did Not Improve From 2001â€2004 to 2009â€2012 as Disparities With Both Publicly and Privately Insured Adults Doubled. Journal of the American Heart Association, 2017, 6, .	1.6	11
65	The impact of metabolic syndrome on metabolic, pro-inflammatory and prothrombotic markers according to the presence of high blood pressure criterion. Clinics, 2013, 68, 1495-1501.	0.6	11
66	Comparative effectiveness research in the â€œrealâ€•world: lessons learned in a study of treatment-resistant hypertension. Journal of the American Society of Hypertension, 2013, 7, 95-101.	2.3	10
67	Chaos to complexity: leveling the playing field for measuring value in primary care. Journal of Evaluation in Clinical Practice, 2017, 23, 430-438.	0.9	10
68	Rationale for Establishing a Mechanism to Increase Reimbursement to Hypertension Specialists. Journal of Clinical Hypertension, 2013, 15, 397-403.	1.0	7
69	Weight Loss Pharmacotherapy: Brief Summary of the Clinical Literature. Ethnicity and Disease, 2015, 25, 511.	1.0	7
70	Aldosterone Antagonists or Renin-Guided Therapy for Treatment-Resistant Hypertension: A Comparative Effectiveness Pilot Study in Primary Care. American Journal of Hypertension, 2016, 29, 976-983.	1.0	7
71	Risk of Hospitalization for Cardiovascular Events with Î²-Blockers in Hypertensive Patients: A Retrospective Cohort Study. Cardiology and Therapy, 2018, 7, 173-183.	1.1	7
72	Blood Pressure Control Among Non-Hispanic Black Adults Is Lower Than Non-Hispanic White Adults Despite Similar Treatment With Antihypertensive Medication: NHANES 2013â€“2018. American Journal of Hypertension, 2022, 35, 514-525.	1.0	7

#	Article	IF	Citations
73	Collectrin, an X-Linked, Angiotensin Converting Enzyme 2 Homolog, Causes Hypertension in a Rat Strain Through Geneâ€"Gene and Geneâ€"Environment Interactions. Circulation, 2013, 128, 1727-1728.	1.6	6
74	Insights on Î²â€blockers for the treatment of hypertension: A survey of health care practitioners. Journal of Clinical Hypertension, 2018, 20, 1464-1472.	1.0	6
75	Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension, 2022, 79, 338-348.	1.3	6
76	Demographic differences in the treatment and control of glucose in type 2 diabetic patients: implications for health care practice. Ethnicity and Disease, 2012, 22, 29-37.	1.0	6
77	Pre-Hypertension: Rationale for Pharmacotherapy. Current Hypertension Reports, 2013, 15, 669-675.	1.5	5
78	Differences in primary cardiovascular disease prevention between the 2013 and 2016 cholesterol guidelines and impact of the 2017 hypertension guideline in the <scp>United States</scp>. Journal of Clinical Hypertension, 2018, 20, 991-1000.	1.0	5
79	Defining Hypertension by Blood Pressure 130/80 mm Hg Leads to an Impressive Burden of Hypertension in Young and Middleâ€Aged Black Adults: Followâ€Up in the CARDIA Study. Journal of the American Heart Association, 2018, 7, .	1.6	5
80	Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Communityâ€Based Practice Registry. Journal of Clinical Hypertension, 2016, 18, 663-671.	1.0	4
81	Influence of acute hyperlipidemia to adipocyte-derived hormones in lean normotensive and subjects with metabolic syndrome. Diabetology and Metabolic Syndrome, 2014, 6, 132.	1.2	3
82	Elijah Saunders in Memoriam. Journal of Clinical Hypertension, 2015, 17, 415-417.	1.0	3
83	CARDIOVASCULAR OUTCOMES WITH NEBIVOLOL, ATENOLOL AND METOPROLOL IN PATIENTS WITH HYPERTENSION: A LARGE, RETROSPECTIVE, PROPENSITY SCORE-MATCHED COHORT STUDY. Journal of the American College of Cardiology, 2017, 69, 1691.	1.2	3
84	Implementation of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Hypertension, 2019, 73, 288-290.	1.3	3
85	Multi-Site Best Practice Discovery: From Free Text to Standardized Concepts to Clinical Decisions. , 2021, , .		3
86	Is life's simple 7 a practical paradigm for promoting healthy blood pressure, preventing cardiovascular disease and improving total health?. Journal of the American Society of Hypertension, 2018, 12, 324-326.	2.3	2
87	Optimal Systolic Blood Pressure Target in Resistant Hypertension. American Journal of Medicine, 2019, 132, e623.	0.6	2
88	Prognostic value of blood pressure control delay in newly diagnosed hypertensive patients. Journal of Hypertension, 2019, 37, 290-291.	0.3	2
89	Challenges and Risks in Attaining the Systolic Blood Pressure Goal of <130 mm Hg in All Diabetic Patients. Journal of Clinical Hypertension, 2006, 8, 50-52.	1.0	1
90	Cardiovascular outcomes in patients with uncontrolled and controlled treatment resistant hypertension. Journal of the American Society of Hypertension, 2014, 8, e49-e50.	2.3	1

#	Article	IF	Citations
91	Effectiveness of a Tailored Behavioral Intervention to Improve Hypertension Control. Hypertension, 2015, 65, 273-275.	1.3	1
92	Is there a role for very lowâ€“dose combination therapy in hypertension management?. Journal of the American Society of Hypertension, 2017, 11, 550-552.	2.3	1
93	Opportunities for improving cardiovascular health outcomes in adults younger than 65Âyears with guidelineâ€recommended statin therapy. Journal of Clinical Hypertension, 2017, 19, 850-860.	1.0	1
94	A Low-cost Adaptable and Personalized Remote Patient Monitoring System. , 2017, , .		1
95	Antihypertensive Treatment in Elderly Frail Patients. Hypertension, 2020, 76, 330-332.	1.3	1
96	Baseline Heart Rate Predicts the Blood Pressure Response to Renal Denervation in Untreated Hypertension. Journal of the American College of Cardiology, 2021, 78, 1039-1041.	1.2	1
97	Other important applications for beta-blockers in high-risk patients. Postgraduate Medicine, 2003, 114, 35-48.	0.9	1
98	Risk factor treatment and control in the stroke belt. American Journal of Hypertension, 2003, 16, A8.	1.0	0
99	Prevalence and treatment of chest pain syndromes, hypertension and high LDL-cholesterol in primary care. American Journal of Hypertension, 2005, 18, A187-A187.	1.0	0
100	Response to Prehypertension: To Treat or Not To Treat Should No Longer Be the Question. Hypertension, 2012, 59, .	1.3	0
101	Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 56-66.	1.0	0
102	Metformin lowers blood pressure in obese and insulin-resistant individuals without diabetes. Journal of the American Society of Hypertension, 2017, 11, 69-70.	2.3	0
103	Does SPRINT support a change in blood pressure targets? The importance of two implicit assumptions and blood pressure measurement methods. Journal of the American Society of Hypertension, 2017, 11, 4-5.	2.3	0
104	Are there cardiometabolic benefits of low-intensity physical activity in at-risk adults?. Journal of the American Society of Hypertension, 2018, 12, 69-70.	2.3	0
105	Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment. Hypertension, 2018, 72, 1090-1092.	1.3	0
106	Is Trump's cardiovascular health â€œexcellentâ€•or are there â€œserious heart concernsâ€? and comments on the president's blood pressure. Journal of the American Society of Hypertension, 2018, 12, 148-150.	2.3	0
107	The prevalence of concurrently raised blood glucose and blood pressure in India. Journal of Hypertension, 2019, 37, 1788-1789.	0.3	0
108	Editorial commentary on â€˜Country of birth and mortality risk in hypertension with and without diabetes: the Swedish Primary Care Cardiovascular Databaseâ€™. Journal of Hypertension, 2021, 39, 1104-1106.	0.3	0

#	Article	IF	Citations
109	Editorial commentary: Racial and Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension, 2021, 78, 1727-1729.	1.3	0
110	Beta-blockers for cardioprotection. A forgotten message?. Postgraduate Medicine, 2003, 114, 3.	0.9	0
111	Thirty years with LIFEâ€"a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure, 2022, 31, 125-128.	0.7	0